Skip to content

Effective treatment of adolescents with aggression problems in clinical and non-clinical settings

Effective treatment of adolescents with aggression problems in clinical and non-clinical settings: a multicentre randomised treatment efficacy trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN21681959
Enrollment
120
Registered
2010-04-06
Start date
2010-07-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aggression regulation problems Mental and Behavioural Disorders Mixed disorders of conduct and emotions

Interventions

Patients are randomised to one of three treatment groups: 1. 30 sessions of aggression replacement training (ART) over a period of 14 weeks 2. Risperidone daily doses from 0.5 to 2 mg 3. Combination o

Sponsors

Karakter - Child and Adolescent Psychiatry (Netherlands)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Full scale intelligence quotient (IQ) at least 80; total IQ (TIQ) less than 75, verbal IQ (VIQ) at least 80 2. Minimal score on Modified Overt Aggression Scale (MOAS) of 5 on both initial screenings 3. Age lies between 12 and 21 years, either sex 4. (Psychiatric) medication free at beginning of the screening procedure 5. Minimal motivation among participant and family 6. Reading level of Avi 6 or 7

Exclusion criteria

Exclusion criteria: 1. Previous ART or risperidone (6 months) 2. Psychotic condition 3. Severe depression 4. Severe substance dependency 5. Suicidal tendencies 6. Pregnancy or lactation 7. Major medical problems 8. Epilepsy 9. Cardiovascular diseases 10. Regular medication which strongly interacts with risperidone 11. Unable to sign informed consent

Design outcomes

Primary

MeasureTime frame
A % decrease in severity and frequency of aggressive behaviour as observed on the MOAS, completed by at least two different informants at baseline and after the intervention period (including follow up measurements after three and six months). A decrease of 40% counts as a response to treatment, between 20 - 30% decrease as a partial response and a decrease below 20% as a non-response.

Secondary

MeasureTime frame
1. Impulsive-Premeditated Aggression Scale (IPAS) at pre-screening, and week 15 2. Clinical Global Impression 'Severity of Illness' (CGI-S) Scale at screening and week 15 3. REactive-PROactive Aggression Questionnaire (REPRO) (for parents, teachers, nurses or pedagogical workers) at screening and week 15 4. Instrument for Reactive and Proactive Aggression (IRPA) at screening and week 15 5. How I Think (HIT) questionnaire at screening and week 15 6. Social Support Questionnaire (SSQ) at screening and week 15 7. Socio-moral Reflection Objective Measure-Short Form (SROM-OSF) at screening and week 15 8. Inventory of callous-unemotional traits (ICU) at screening and week 15 9. Reactive-Proactive Aggression Questionnaire (RPQ) (for youths) at screening and week 15

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026